Cliff Asness's RYTM Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 59,279 shares of Rhythm Pharmaceuticals, Inc. (RYTM) worth $5.16 M, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in RYTM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 56,017 shares. Largest reduction occurred in Q3 2024, reducing 71,021 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Rhythm Pharmaceuticals (RYTM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Rhythm Pharmaceuticals (RYTM) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -10,767 | Reduce 15.37% | 59,279 | $86.97 |
| Q4 2025 | -9,734 | Reduce 12.20% | 70,046 | $107.04 |
| Q3 2025 | +30,740 | Add 62.68% | 79,780 | $100.99 |
| Q2 2025 | +9,677 | Add 24.58% | 49,040 | $63.19 |
| Q1 2025 | +23,506 | Add 148.24% | 39,363 | $52.97 |
| Q4 2024 | -16,952 | Reduce 51.67% | 15,857 | $55.98 |
| Q3 2024 | -71,021 | Reduce 68.40% | 32,809 | $52.39 |
| Q2 2024 | +32,831 | Add 46.24% | 103,830 | $41.06 |
| Q1 2024 | +56,017 | Add 373.90% | 70,999 | $43.33 |
| Q4 2023 | -5,314 | Reduce 26.18% | 14,982 | $45.97 |
| Q3 2023 | +7,580 | Add 59.61% | 20,296 | $22.93 |
| Q2 2023 | +12,716 | New Buy | 12,716 | $16.49 |
| Q3 2022 | -10,295 | Sold Out | 0 | $0.00 |
| Q2 2022 | +164 | Add 1.62% | 10,295 | $4.18 |
| Q1 2022 | +10,131 | New Buy | 10,131 | $11.55 |
| Q4 2021 | -10,191 | Sold Out | 0 | $0.00 |
| Q3 2021 | +10,191 | New Buy | 10,191 | $13.05 |
Cliff Asness's Rhythm Pharmaceuticals Investment FAQs
Cliff Asness first purchased Rhythm Pharmaceuticals, Inc. (RYTM) in Q3 2021, acquiring 10,191 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Rhythm Pharmaceuticals, Inc. (RYTM) for 17 quarters since Q3 2021.
Cliff Asness's largest addition to Rhythm Pharmaceuticals, Inc. (RYTM) was in Q1 2024, adding 70,999 shares worth $3.08 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 59,279 shares of Rhythm Pharmaceuticals, Inc. (RYTM), valued at approximately $5.16 M.
As of the Q1 2026 filing, Rhythm Pharmaceuticals, Inc. (RYTM) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Rhythm Pharmaceuticals, Inc. (RYTM) was 103,830 shares, as reported at the end of Q2 2024.